IMARC Group, a leading market research company, has recently releases report titled “Viral Inactivation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global viral inactivation market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How big is the viral inactivation market?
The global viral inactivation market size reached US$ 577.3 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,028.4 Million by 2028, exhibiting a growth rate (CAGR) of 9.4% during 2023-2028.
What is the viral inactivation?
A virus is a type of infectious particle that invades cells and proliferates, resulting in various diseases. Viral inactivation is one of the first steps designed to enhance the efficacy and safety of biotherapeutic products. It helps stop the viruses in a given sample from contaminating the product by rendering them non-infectious or eliminating their presence entirely. The technique is widely used in the blood plasma in the food industries to prevent the presence of viral particles. Currently, several methods of viral inactivation are available in the market, depending on the various characteristics of the virus and the type of biotherapeutic product.
Request Free Report Sample: https://www.imarcgroup.com/viral-inactivation-market/requestsample
The global viral inactivation market is primarily driven by the rising number of chronic diseases, such as cancer, autoimmune diseases, and diabetes. In line with this, governments of various nations are heavily investing in the advancement of the healthcare industry. They are also introducing stringent regulatory standards in the development of biotherapeutic products at an early stage, which is providing a considerable boost to the market growth.
Moreover, the surging concerns about the transmission of blood-borne viruses and the increasing investments in research and development (R&D) activities are boosting the market growth. Additionally, key players are developing new physical methods, such as gas plasma, supercritical fluids, and pulsed electric fields, to increase the suitability, reliability, and convenience of viral inactivation, which is accelerating the market growth.
Competitive Landscape With Key Players:
The competitive landscape of the global viral inactivation market has been studied in the report with the detailed profiles of the key players operating in the market.
- Charles River Laboratories (NYSE: CRL)
- Merck KGaA
- Parker Hannifin Corp
- Rad Source Technologies
- Sartorius AG
- SGS SA
- Terumo Corporation
- Vironova AB
- WuXi AppTec
Explore Full Report Description At: https://www.imarcgroup.com/viral-inactivation-market
Key Market Segmentation:
- Reagents and Kits
- Vaccines and Therapeutics
- Stem Cell Products
- Blood and Blood Products
- Tissue and Tissue Products
- Cellular and Gene Therapy
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: [email protected]
Follow us on Twitter: @imarcglobal